OncRef
Skip to newsletter content
|
mCRPCOctober 2026
0:00 / 2:53
Metastatic Castration Resistant Prostate Cancer — Monthly Compass
Oct 01–31, 2026 • Priority Updates • 3–5 minute read
 
A curated, practice-minded digest of what moved in metastatic castration resistant prostate cancer this month — regulatory signals, clinical development, and the most practice-relevant publications.
Built for oncologists OncRef Curated Oncology Intelligence Layer
metastatic castration resistant prostate cancer updates
Key Highlights
Key Highlights
  • Practice-Changing Updates
    • CCTG PR21 showed that 177Lu‑PSMA‑617 improved patient‑reported quality of life versus docetaxel in PSMA‑PET–positive, post‑ARPI mCRPC, supporting radioligand therapy as a chemo‑sparing option.
    • Quality‑of‑life–forward radioligand therapy data are expected to influence payer and guideline emphasis on patient‑reported outcomes in late‑line treatment selection.
  • Key Clinical Development Updates
    • The FDA granted Fast Track designation to VIR‑5500, a PSMA‑targeted dual‑masked T‑cell engager for late‑line mCRPC, with an ongoing phase 1 spanning monotherapy and early‑line combinations and pivotal phase 3 trials anticipated in 2027.
    • FL‑020, a PSMA‑targeted alpha radiopharmaceutical, received FDA Fast Track and reported preliminary phase 1 PSA declines with favorable safety at ESMO 2026, with a phase 2 dose‑optimization study planned in alignment with recent FDA draft guidance.
  • Key Conference Updates
    • At ESMO 2026, JNJ‑6143, a first‑in‑class RIPTAC that uses an AR‑guided dual‑protein lock to sequester BRD4, elicited deep PSA declines and radiographic responses with a manageable adverse‑event profile in heavily pretreated mCRPC.
    • ESMO 2026 highlighted high PSA50 and RECIST responses with favorable tolerability for the 212Pb‑PSMA alpha therapy ADVC001 and unveiled plasma epigenomic signatures delineating lineage/WNT versus AR‑luminal states associated with radioligand therapy response and resistance.
  • Emerging Themes & Macro-Trends
    • Non‑chemotherapy strategies are ascendant in mCRPC, with PSMA radiotherapeutics, first‑in‑class small molecules such as RIPTACs, epigenetic/PI3K‑pathway combinations, and B7‑H3 ADCs collectively driving a more personalized and better‑tolerated late‑line landscape.
    • Strategic priorities center on PSMA‑alpha platforms, ctDNA/epigenomic patient selection, and resistance‑biology combinations (PI3K/PRC2+AR), while B7‑H3 ADCs advance into taxane‑naïve registrational testing with BNT324‑03 versus docetaxel and near‑term efforts emphasize signal‑seeking and pivotal‑enablement over filings.
FDA Approvals/Withdrawals
FDA Approvals/Withdrawals
  • There are no press releases between 2026-10-01 and 2026-10-31 about metastatic castration resistant prostate cancer.
Clinical Development Regulatory Updates
Clinical Development Regulatory Updates
  • Vir Biotechnology announced that the FDA granted Fast Track designation to VIR-5500, a PSMA-targeted dual-masked T-cell engager, for late-line metastatic castration-resistant prostate cancer. The ongoing phase 1 includes mCRPC monotherapy and early-line combination cohorts, with pivotal phase 3 trials anticipated in 2027.¹ (investors.vir.bio) (read more)
  • Full-Life Technologies reported phase 1 mCRPC data for the PSMA-targeted alpha radiopharmaceutical [225Ac]Ac-FL-020 at ESMO 2026 and noted the FDA has granted Fast Track Designation to FL-020. The company highlighted PSA declines and a favorable safety profile and plans a phase 2 dose-optimization study aligned with recent FDA draft guidance.² (prnewswire.com) (read more)
  • Johnson & Johnson presented phase 1 results for the RIPTAC molecule JNJ-6143 in heavily pretreated mCRPC and reiterated that the agent received FDA Fast Track designation in August 2025. Investigators reported deep PSA declines and radiographic responses supporting continued development.³ (targetedonc.com) (read more)
Conference
Major Conference Updates
Conference Information
  • ESMO Congress 2026, Madrid, Spain; October 23–27, 2026.
  • Overall sentiment: Clear momentum toward non-chemotherapy options in mCRPC, with PSMA radiotherapeutics, first‑in‑class small molecules (RIPTACs), epigenetic/PI3K-pathway combinations, and ADCs signaling a more personalized, better‑tolerated late‑line landscape. (read more)
  • -THEME 1: PSMA Radiotherapeutics Move Beyond “if” to “how best”—
  • Significance: Beta and alpha PSMA RLTs are differentiating on quality of life and durability, while blood‑based biology begins to guide sequencing. (read more)
  • Mechanism insights / clinical impact: 177Lu‑PSMA‑617 improved patient‑reported QoL vs docetaxel in PR21, reinforcing RLT as a chemo‑sparing option; emerging 212Pb‑PSMA alpha therapy (ADVC001) showed high PSA50 and RECIST responses with favorable tolerability, suggesting deeper, faster cell kill; plasma epigenomics identified lineage/WNT vs AR‑luminal states associated with RLT response/resistance, informing rational combinations. (read more)
  • Patient populations affected: PSMA‑PET–positive, post‑ARPI mCRPC (mAPMR); interest in extending alpha therapy to mAPMS. (read more)
  • -THEME 2: Novel Non‑AR Mechanisms (RIPTACs, T‑cell Engagers)—
  • Significance: Platforms that kill AR‑dependent tumors without relying on classic AR blockade could redefine late‑line care. (read more)
  • Mechanism insights / clinical impact: JNJ‑6143 (RIPTAC) uses an AR‑guided dual‑protein lock to sequester BRD4, producing notable PSA/tumor responses with manageable AE profile; bispecific T‑cell engagers gained visibility as a targeted immunotherapy avenue for mCRPC/NEPC. (read more)
  • Patient populations affected: Heavily pretreated mCRPC including high‑risk molecular subsets; potential utility in PSMA‑non‑avid or AR‑refractory disease niches. (read more)
  • -THEME 3: Overcoming Resistance with Combination Biology—
  • Significance: Convergent targeting of PI3K/AKT/mTOR, AR, and PRC2 pathways aims to delay/overcome ARPI resistance and maintain luminal/AR dependence. (read more)
  • Mechanism insights / clinical impact: Gedatolisib + darolutamide (CELC‑G‑201) showed preliminary activity and tolerability post‑ARPI; translational data for “rinzimetostat” (next‑gen PRC2 inhibitor) support enhancing AR signaling and restricting lineage plasticity, including activity against EZH2‑mutational escape seen with earlier agents. (read more)
  • Patient populations affected: Post‑ARPI mCRPC, including PTEN‑altered and lineage‑plastic tumors where cross‑pathway targeting may restore sensitivity. (read more)
  • -THEME 4: ADCs Challenging Docetaxel in Taxane‑Naïve mCRPC—
  • Significance: B7‑H3 ADCs are moving into registrational positioning against docetaxel, signaling a chemo‑sparing intent in earlier mCRPC lines. (read more)
  • Mechanism insights / clinical impact: “Elfetabart drozuntecan” (DB‑1311/BNT324) Phase 3 “BNT324‑03” vs docetaxel underscores ADC momentum in prostate cancer, leveraging tumor‑associated B7‑H3 expression. (read more)
  • Patient populations affected: Taxane‑naïve mCRPC across global sites; comparator choice positions ADCs for broad adoption if outcomes and tolerability outperform chemo. (read more)
  • Significance
    • Expected clinical or translational readouts: RIPTAC program expanding (Phase 2 underway; Phase 3 imminent); ADVC001 Phase 2 enrolling; PRC2‑AR combination strategies maturing; BNT324‑03 progressing toward pivotal endpoints. (read more)
    • Regulatory or policy implications: Near‑term is signal‑seeking/pivotal enablement rather than filings; QoL‑forward RLT data may influence payer and guideline emphasis on patient‑reported outcomes in late‑line choices. (read more)
    • Potential shifts in standard of care: Increased preference for PSMA RLT over docetaxel in eligible post‑ARPI mCRPC; ADCs and RIPTACs could open non‑chemo backbones in taxane‑naïve and refractory settings. (read more)
    • Strategic implications: Invest behind PSMA‑alpha, ctDNA/epigenomic selection, and chemo‑replacement ADCs; prioritize resistance‑biology combos (PI3K/PRC2+AR) to secure durable benefit in molecularly complex mCRPC. (read more)
Publications Related to Approved Drugs
Talazoparib plus enzalutamide versus placebo plus enzalutamide in metastatic androgen pathway modulator-resistant (castration-resistant) prostate cancer (TALAPRO-2): a biomarker analysis of circulating tumour DNA and cells for prognosis and molecular profiling. A biomarker analysis of the Phase 3 TALAPRO-2 trial demonstrated the prognostic value of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in patients with metastatic castration-resistant prostate cancer (mCRPC). The study found that baseline ctDNA burden and on-treatment reductions in ctDNA and CTCs were associated with improved radiographic progression-free survival, supporting the use of liquid biopsies to monitor patients receiving talazoparib plus enzalutamide. () .
Efficacy and Safety of Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Non-BRCA Mutation Subgroup of Patients with Metastatic Castration-resistant Prostate Cancer in the PROpel Trial. In a post-hoc analysis of the Phase 3 PROpel trial, the combination of olaparib and abiraterone demonstrated a numerically longer radiographic progression-free survival (24.1 vs 19.0 months) compared to placebo plus abiraterone in patients with non-BRCA mutated metastatic castration-resistant prostate cancer (mCRPC). These findings suggest that olaparib plus abiraterone is a viable treatment option for this patient subgroup, with a safety profile consistent with the overall trial population. () .
Efficacy of Olaparib Plus Abiraterone for Patients with Metastatic Castration-resistant Prostate Cancer and Single Homologous Recombination Repair Gene Mutations in PROpel. An analysis from the Phase 3 PROpel trial highlights the efficacy of olaparib plus abiraterone in first-line metastatic castration-resistant prostate cancer (mCRPC) patients with single homologous recombination repair gene mutations (HRRm). The data showed strong numerical favorability for both radiographic progression-free survival and overall survival, particularly in patients with BRCA2 mutations, reinforcing this combination as a critical first-line option for the HRRm population. () .
Association between concomitant ACEI/ARBs use and survival of patients with prostate cancer receiving abiraterone acetate: A post-hoc analysis of two randomized trials. A post-hoc analysis of the COU-AA-301 and COU-AA-302 trials revealed that the concomitant use of ACE inhibitors or angiotensin receptor blockers (ACEI/ARBs) was associated with improved radiographic progression-free survival (rPFS), overall survival (OS), and prostate cancer-specific survival (PCSS) in patients receiving abiraterone acetate. These findings suggest a potential beneficial interaction between these antihypertensive agents and abiraterone acetate, meriting further prospective investigation. (, ) .
Testosterone breakthrough and outcomes during intensified therapy in metastatic hormone-sensitive prostate cancer: the ARASENS and LATITUDE trials. In a post-hoc analysis of the LATITUDE trial, testosterone breakthrough (>35 ng/dL) was associated with worse overall survival for patients with metastatic hormone-sensitive prostate cancer receiving abiraterone acetate plus prednisone and ADT. However, this association was not statistically significant in the ARASENS trial for patients receiving darolutamide plus ADT and docetaxel, highlighting that the clinical implications of testosterone breakthrough may vary with different intensified therapeutic regimens. (, ) .
Neuropeptides and their receptors in CNS cancer imaging/theranostics: Review of recent advances and increased interest with emphasis on the somatostatin/bombesin/substance P peptide receptor families. This review highlights the expanding field of peptide-directed theranostics, referencing the success of Lutetium Lu 177 vipivotide tetraxetan in the VISION trial for advanced prostate cancer as a foundational example. The paper discusses the scientific basis and future potential of applying similar peptide receptor targeting strategies, particularly using somatostatin, bombesin, and substance P receptor families, to CNS tumors. () .
New Publications Related to Drugs in Clinical Trial Development
Clonal circulating tumor cell mobilization following chimeric antigen receptor T-cell therapy in metastatic castration-resistant prostate cancer. This exploratory analysis of a CAR-T clinical trial utilized a high-resolution, single-cell liquid biopsy to monitor the circulatory tumor landscape in mCRPC patients. The study found that responders to therapy demonstrated a post-infusion reduction in clonal circulating tumor cells (CTCs), whereas non-responders exhibited persistence, suggesting that longitudinal, enrichment-free single-cell analysis is a feasible method to monitor clonal heterogeneity and treatment response. ()
TheraPb Phase 1b: First-in-Human Dose-Escalation and Optimization Study of 212Pb-ADVC001 in PSMA-Positive Metastatic Androgen Pathway Modulation-Resistant Prostate Cancer. The first-in-human study of 212Pb-ADVC001, a PSMA-targeted alpha-emitter radiopharmaceutical, showed that the treatment was well-tolerated and demonstrated encouraging anti-tumor activity in heavily pretreated mCRPC patients. At the recommended phase 2 doses of 160 and 200 MBq, 80% of participants achieved a PSA decline of ≥50%, and the overall response rate was 100% in RECIST-evaluable patients, supporting further evaluation in phase 2. ()
Pembrolizumab Plus Lenvatinib in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort E. In the KEYNOTE-365 study, the combination of pembrolizumab plus lenvatinib was evaluated in patients with mCRPC previously treated with docetaxel. The regimen demonstrated notable antitumor activity, with a confirmed prostate-specific antigen (PSA) response rate of 34% and an objective response rate (ORR) of 36% in patients with measurable disease, although grade 3-5 treatment-related adverse events were observed in 62% of participants. ()
Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [177Lu] Lu-PSMA-617 (ANZUP1901). This sub-study of the ENZA-p trial demonstrated that PSMA-total-tumor-volume (PSMA-TTV) measured by PSMA-PET/CT at 3 months is a significant prognostic biomarker for overall survival in mCRPC. An increase in PSMA-TTV or a higher residual tumor volume at this interim timepoint was strongly associated with shorter survival, independent of the treatment received or PSA response, highlighting its potential to guide clinical decisions. ()
Nivolumab and cabozantinib in people with HIV and advanced solid tumors: a pilot trial and systematic review. This pilot trial, which included a prostate cancer patient, established that the combination of nivolumab and cabozantinib has a manageable safety profile for people living with HIV (PWH) and advanced solid tumors, without negatively impacting HIV virologic control. The findings support the inclusion of PWH in larger, dedicated studies of combination immunotherapy and targeted therapy, particularly as durable disease stabilization was observed in some participants. ()
Clinical Trials
Clinical Trials Summary
Number of Clinical Trials in metastatic castration resistant prostate cancer updated from 2026-10-01 to 2026-10-31:
Phase 1Phase 1/2Phase 2Phase 2/3Phase 3Phase 4Total
Enrolling by Invitation-------
Not Yet Recruiting3111--6
Recruiting161510-9-50
Available-------
Approved for Marketing-------
Active, Not Recruiting648-1120
Completed-------
Total252019110176
Phase 1 Clinical Trials within 3 Months of Primary Completion Date:
No phase 1 trials completing within the next three months.
Phase 2 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
ARPI: Abiraterone, AAA617, ARPI: Enzalutamide NCT06894511 ACTIVE_NOT_RECRUITING A Phase II, Open-label, Multi-Center, Randomized Study of Combination of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) and Androgen Receptor Pathway Inhibitor (ARPI) vs. Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in First-line Treatment of Patients With Prostate-Specific Membrane Antigen (PSMA)-Positive Progressive Metastatic Castration Resistant Prostate Cancer (mCRPC) 2026-10-15
Phase 3 Clinical Trials within 3 Months of Primary Completion Date:
No phase 3 trials completing within the next three months.
Phase 4 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
ARPI therapy, Radium-223 dichloride (Xofigo, BAY88-8223) NCT04597125 ACTIVE_NOT_RECRUITING A Phase 4, Randomized, Open-label, Multicenter Efficacy and Safety Study of Standard Dose of Radium-223 Dichloride vs. Standard Doses of Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Bone Dominant Metastatic Castration Resistant Prostate Cancer (mCRPC) Progressing on/After One Line of ARPI 2026-11-19
NOTICE: This communication may contain confidential or proprietary information of Oncology Reference, Inc. Data is compiled from publicly available and third-party sources and integrated with proprietary Oncology Reference database mappings, developed and maintained by PhD scientists and advanced AI systems, for organization and analysis. While reasonable efforts are made to ensure accuracy and timeliness, Oncology Reference, Inc. makes no representation or warranty, express or implied, regarding accuracy, completeness, or fitness for a particular purpose. Information may contain errors, omissions, or be subject to change without notice. This material is for informational purposes only and is not medical advice, regulatory guidance, investment advice, or a substitute for professional judgment. Users must independently verify all information.

Oncology Reference, Inc. and its affiliates disclaim all liability for any loss or damage arising from use of or reliance on this information. By using this information, you agree that disputes will be governed by Delaware law and resolved by binding arbitration in Delaware.
California residents waive California Civil Code § 1542. All trademarks are the property of their respective owners.
© 2025 Oncology Reference, Inc. All rights reserved.

CONFIDENTIALITY NOTICE: If you are not the intended recipient, please notify the sender, delete this message, and refrain from using or disclosing its contents.